Abstract
ObjectivesWith the wide range of biological disease-modifying anti-rheumatic drugs (bDMARDs) available for treating rheumatoid arthritis (RA), and limited evidence to guide the choice for individual patients, we wished to evaluate...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have